Adc Therapeutics Sa Stock EBITDA

ADCT Stock

USD 1.79 0.06 3.24%

ADC Therapeutics SA fundamentals help investors to digest information that contributes to ADC Therapeutics' financial success or failures. It also enables traders to predict the movement of ADC Stock. The fundamental analysis module provides a way to measure ADC Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ADC Therapeutics stock.

		Last Reported	Projected for Next Year
	EBITDA	-132.1 M	-138.7 M

EBITDA is likely to drop to about (138.7 M) in 2025.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

ADC Therapeutics SA Company EBITDA Analysis

ADC Therapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current ADC Therapeutics EBITDA

(146.76 M)

Most of ADC Therapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ADC Therapeutics SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

ADC EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for ADC Therapeutics is extremely important. It helps to project a fair market value of ADC Stock properly, considering its historical fundamentals such as EBITDA. Since ADC Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ADC Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ADC Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Net Tangible Assets	Capital Surpluse	Net Invested Capital	Net Working Capital	Property Plant Equipment	Capital Stock	Short Term Debt	Long Term Debt	Long Term Investments	Short Long Term Debt	Deferred Long Term Liab
Total Assets		-0.11	0.52	-0.74	-0.79	0.73	0.68	0.78	1.0	0.83	0.83	-0.34	-0.24	0.0	0.86	0.8	0.83	0.7	0.04	-0.45	0.61	0.49
Total Stockholder Equity	-0.11		-0.77	-0.52	0.65	-0.62	-0.39	-0.7	-0.15	-0.5	-0.46	0.8	0.65	0.94	0.06	-0.54	-0.5	0.32	0.41	0.9	-0.76	-0.81
Current Deferred Revenue	0.52	-0.77		0.07	-0.73	0.78	0.69	0.85	0.54	0.63	0.53	-0.74	-0.61	-0.67	0.38	0.68	0.57	0.03	-0.28	-0.82	0.82	0.78
Net Debt	-0.74	-0.52	0.07		0.25	-0.23	-0.15	-0.21	-0.73	-0.35	-0.38	-0.29	-0.17	-0.57	-0.76	-0.29	-0.36	-0.86	-0.39	-0.15	0.03	0.15
Retained Earnings	-0.79	0.65	-0.73	0.25		-0.91	-0.7	-0.96	-0.8	-0.95	-0.94	0.76	0.51	0.58	-0.5	-0.93	-0.95	-0.3	0.23	0.86	-0.89	-0.84
Accounts Payable	0.73	-0.62	0.78	-0.23	-0.91		0.68	0.88	0.76	0.93	0.84	-0.74	-0.37	-0.59	0.43	0.89	0.84	0.24	-0.08	-0.8	0.91	0.85
Net Receivables	0.68	-0.39	0.69	-0.15	-0.7	0.68		0.71	0.67	0.71	0.68	-0.61	-0.17	-0.27	0.5	0.74	0.68	0.13	-0.25	-0.49	0.8	0.71
Total Liab	0.78	-0.7	0.85	-0.21	-0.96	0.88	0.71		0.8	0.88	0.86	-0.73	-0.64	-0.59	0.58	0.89	0.89	0.29	-0.28	-0.89	0.88	0.84
Total Current Assets	1.0	-0.15	0.54	-0.73	-0.8	0.76	0.67	0.8		0.84	0.84	-0.34	-0.26	-0.03	0.86	0.81	0.84	0.68	0.03	-0.49	0.63	0.52
Intangible Assets	0.83	-0.5	0.63	-0.35	-0.95	0.93	0.71	0.88	0.84		0.97	-0.72	-0.33	-0.47	0.49	0.97	0.96	0.39	-0.07	-0.72	0.86	0.78
Common Stock	0.83	-0.46	0.53	-0.38	-0.94	0.84	0.68	0.86	0.84	0.97		-0.62	-0.32	-0.38	0.56	0.96	0.99	0.42	-0.09	-0.69	0.82	0.75
Net Tangible Assets	-0.34	0.8	-0.74	-0.29	0.76	-0.74	-0.61	-0.73	-0.34	-0.72	-0.62		0.5	0.86	0.07	-0.74	-0.65	0.13	0.33	0.75	-0.76	-0.75
Capital Surpluse	-0.24	0.65	-0.61	-0.17	0.51	-0.37	-0.17	-0.64	-0.26	-0.33	-0.32	0.5		0.62	-0.17	-0.32	-0.41	0.11	0.7	0.72	-0.43	-0.54
Net Invested Capital	0.0	0.94	-0.67	-0.57	0.58	-0.59	-0.27	-0.59	-0.03	-0.47	-0.38	0.86	0.62		0.29	-0.47	-0.42	0.43	0.43	0.83	-0.67	-0.73
Net Working Capital	0.86	0.06	0.38	-0.76	-0.5	0.43	0.5	0.58	0.86	0.49	0.56	0.07	-0.17	0.29		0.51	0.56	0.73	0.13	-0.26	0.37	0.27
Property Plant Equipment	0.8	-0.54	0.68	-0.29	-0.93	0.89	0.74	0.89	0.81	0.97	0.96	-0.74	-0.32	-0.47	0.51		0.95	0.42	0.0	-0.71	0.85	0.75
Capital Stock	0.83	-0.5	0.57	-0.36	-0.95	0.84	0.68	0.89	0.84	0.96	0.99	-0.65	-0.41	-0.42	0.56	0.95		0.41	-0.16	-0.73	0.82	0.76
Short Term Debt	0.7	0.32	0.03	-0.86	-0.3	0.24	0.13	0.29	0.68	0.39	0.42	0.13	0.11	0.43	0.73	0.42	0.41		0.59	0.08	-0.01	-0.17
Long Term Debt	0.04	0.41	-0.28	-0.39	0.23	-0.08	-0.25	-0.28	0.03	-0.07	-0.09	0.33	0.7	0.43	0.13	0.0	-0.16	0.59		0.43	-0.3	-0.48
Long Term Investments	-0.45	0.9	-0.82	-0.15	0.86	-0.8	-0.49	-0.89	-0.49	-0.72	-0.69	0.75	0.72	0.83	-0.26	-0.71	-0.73	0.08	0.43		-0.87	-0.91
Short Long Term Debt	0.61	-0.76	0.82	0.03	-0.89	0.91	0.8	0.88	0.63	0.86	0.82	-0.76	-0.43	-0.67	0.37	0.85	0.82	-0.01	-0.3	-0.87		0.97
Deferred Long Term Liab	0.49	-0.81	0.78	0.15	-0.84	0.85	0.71	0.84	0.52	0.78	0.75	-0.75	-0.54	-0.73	0.27	0.75	0.76	-0.17	-0.48	-0.91	0.97

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict ADC Therapeutics

Ebitda Over Time

ADC Ebitda

Ebitda

(138.69 Million)

At this time, ADC Therapeutics' EBITDA is comparatively stable compared to the past year.

According to the company disclosure, ADC Therapeutics SA reported earnings before interest,tax, depreciation and amortization of (146.76 Million). This is 116.73% lower than that of the Communications Equipment sector and 246.53% lower than that of the Information Technology industry. The ebitda for all United States stocks is 103.76% higher than that of the company.

ADC EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ADC Therapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ADC Therapeutics could also be used in its relative valuation, which is a method of valuing ADC Therapeutics by comparing valuation metrics of similar companies.

ADC Therapeutics is currently under evaluation in ebitda category among its peers.

ADC Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of ADC Therapeutics from analyzing ADC Therapeutics' financial statements. These drivers represent accounts that assess ADC Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ADC Therapeutics' important valuation drivers and their relationship over time.

	2020	2021	2022	2023	2024	2025 (projected)
Market Cap	2.1B	1.6B	300.1M	135.6M	156.0M	148.2M
Enterprise Value	1.7B	1.2B	91.0M	(18.6M)	(21.4M)	(20.3M)

ADC Therapeutics Institutional Holders

Institutional Holdings refers to the ownership stake in ADC Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of ADC Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ADC Therapeutics' value.

		Shares
Ubs Group Ag	2024-12-31	884.5 K
Vantage Consulting Group Inc.	2024-12-31	850.7 K
Blue Owl Capital Holdings Lp	2024-12-31	733.6 K
Bnp Paribas Arbitrage, Sa	2024-12-31	716.7 K
Vanguard Group Inc	2024-12-31	644.6 K
Northern Trust Corp	2024-12-31	476.2 K
Millennium Management Llc	2024-12-31	411.1 K
Wellington Management Company Llp	2024-12-31	253.3 K
Dafna Capital Management Llc	2024-12-31	224.1 K
Redmile Group, Llc	2024-12-31	15.7 M
Prosight Management, Lp	2024-12-31	9.5 M

ADC Fundamentals

	Return On Equity	-7.06
	Return On Asset	-0.21
	Profit Margin	(3.00) %
	Operating Margin	(1.93) %
	Current Valuation	29.15 M
	Shares Outstanding	96.69 M
	Shares Owned By Insiders	20.64 %
	Shares Owned By Institutions	63.17 %
	Number Of Shares Shorted	5.3 M
	Price To Earning	19.80 X
	Price To Book	2.58 X
	Price To Sales	2.53 X
	Revenue	69.56 M
	Gross Profit	(59.85 M)
	EBITDA	(146.76 M)
	Net Income	(240.05 M)
	Cash And Equivalents	376.78 M
	Cash Per Share	4.90 X
	Total Debt	124.38 M
	Debt To Equity	2.75 %
	Current Ratio	5.76 X
	Book Value Per Share	(1.78) X
	Cash Flow From Operations	(118.69 M)
	Short Ratio	11.50 X
	Earnings Per Share	(2.39) X
	Price To Earnings To Growth	0.74 X
	Target Price	8.8
	Number Of Employees	273
	Beta	1.52
	Market Capitalization	178.88 M
	Total Asset	354.78 M
	Retained Earnings	(1.34 B)
	Working Capital	268.62 M
	Current Asset	1.11 B
	Current Liabilities	288.7 M
	Net Asset	354.78 M

About ADC Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze ADC Therapeutics SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ADC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ADC Therapeutics SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for ADC Stock Analysis

When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC